Medicenna Therapeutics
Toronto
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines (ECs) for the treatment of a broad range of cancers. Its proprietary technology platform supports a unique, multi-methodology treatment paradigm that can precisely deliver potent cell-killing agents for cancer as well as actively alter the immunosuppressive tumor micro-environment without harming healthy cells. The company was founded in 2012 and based in Toronto, Ontario, Canada.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $73.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2024)
- Ticker: tsx:MDNA
- Website: medicenna.com
- Phone: +1-866-393-4891
Industries & Categories
Biotechnology, Health Care, Medical, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/medicenna-therapeutics-57698 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.